Mylan

Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Mylan's Lantus copy derailed in U.S. again by manufacturing ills
Fierce Pharma
Mylan
Lantus
generics
Biocon
drug manufacturing
diabetes
Flag link:
Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022
Mylan's Newly-Approved Alimta Generic Will Not be Sold Until 2022
BioSpace
Eli Lilly
Mylan
Alimta
FDA
generics
lung cancer
Flag link:
Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta
Mylan up on OK for generic of Lilly’s $2bn cancer drug Alimta
Pharmaforum
Mylan
Eli Lilly
generics
Alimta
non-squamous non-small cell lung cancer
mesothelioma
Flag link:
Novo Nordisk and Mylan Battle Over Generic Versions of Victoza
Novo Nordisk and Mylan Battle Over Generic Versions of Victoza
BioSpace
Novo Nordisk
Mylan
generics
Victoza
diabetes
Flag link:
3 generic drugmakers accused of 'stonewalling' congressional probe
3 generic drugmakers accused of 'stonewalling' congressional probe
Beckers Hospital Review
generics
Mylan
Teva Pharmaceutical
Heritage Pharmaceuticals
Flag link:
Mylan-Upjohn Merger Leaves Analysts Skeptical
Mylan-Upjohn Merger Leaves Analysts Skeptical
Xtalks
analysts
M&A
Mylan
Pfizer
Upjohn
Flag link:
After Mylan Gets Acquired, Could Teva Be Next?
After Mylan Gets Acquired, Could Teva Be Next?
Yahoo/Guru Focus
Pfizer
Upjohn
Mylan
Teva Pharmaceutical
M&A
Flag link:
Pfizer may send EpiPen manufacturing to generics spinoff
Pfizer may send EpiPen manufacturing to generics spinoff
Biopharma Dive
Pfizer
Mylan
M&A
Meridian Medical Technologies
EpiPens
drug shortages
Flag link:
Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger
Plagued by production issues, Pfizer aims to shift EpiPen work to Mylan-Upjohn merger
Fierce Pharma
Mylan
Pfizer
Upjohn
EpiPens
drug shortages
Flag link:
How Mylan ended as a junior partner in its Pfizer deal
How Mylan ended as a junior partner in its Pfizer deal
Biopharma Dive
Mylan
Pfizer
Perrigo
Teva Pharmaceutical
M&A
Flag link:
With Mylan deal, Pfizer seeks faster growth via innovation focus
With Mylan deal, Pfizer seeks faster growth via innovation focus
BioCentury
Pfizer
Mylan
M&A
Upjohn
innovation
Flag link:
What The Pfizer-Mylan Deal Means For Pharma
What The Pfizer-Mylan Deal Means For Pharma
Forbes
Pfizer
Mylan
M&A
Flag link:
Mylan CEO Heather Bresch to retire after deal to merge with Pfizer's Upjohn closes
Mylan CEO Heather Bresch to retire after deal to merge with Pfizer's Upjohn closes
Marketwatch
Mylan
Pfizer
M&A
Pharma CEOs
Heather Bresch
Flag link:
Pfizer and Mylan: Is Mega-Merger on the Horizon?
Pfizer and Mylan: Is Mega-Merger on the Horizon?
Market Realist
Pfizer
off-patent
Mylan
Upjohn
M&A
Flag link:
Pfizer in talks to merge off-patent drugs business with Mylan -source
Pfizer in talks to merge off-patent drugs business with Mylan -source
Yahoo/Reuters
Pfizer
Mylan
M&A
Flag link:
Opioid and price fixing legal liabilities mount for generic companies
Opioid and price fixing legal liabilities mount for generic companies
Biopharma Dive
generics
opioids
price fixing
Purdue Pharma
Mylan
Endo
Amneal
Teva Pharmaceutical
Flag link:
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gap
Fierce Pharma
Novartis
Mylan
Pfizer
EpiPens
Sandoz
Symjepi
drug launches
Adamis Pharmaceuticals
Flag link:
Supply constraints push EpiPen rival maker Amneal to restructure, shares fall
Supply constraints push EpiPen rival maker Amneal to restructure, shares fall
Endpoints
Amneal
Mylan
EpiPens
generics
Flag link:
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
With FDA spanking, Biocon and Mylan face new hurdle for Lantus challenger
Fierce Pharma
FDA
Biocon
Mylan
Sanofi
Lantus
insulin
drug manufacturing
Flag link:
Mylan investors favor expanding exec pay clawbacks. Will the company listen?
Mylan investors favor expanding exec pay clawbacks. Will the company listen?
Fierce Pharma
Mylan
executive pay
Flag link:

Pages